

An Evidence-Based Analysis of Novel and Emerging Botanical Medicines for Hyperlipoproteinemia: Efficacy, Mechanisms, and Clinical Considerations

Executive Summary

This report provides a critical, evidence-based analysis of the efficacy, mechanisms, and safety profiles of novel and emerging natural compounds for managing hyperlipoproteinemia. It synthesizes findings from recent meta-analyses, clinical trials, and preclinical research to offer a nuanced understanding of their potential as complementary or alternative therapies. While several compounds—most notably berberine and artichoke leaf extract—show significant promise based on pooled data from clinical trials, a critical review reveals pervasive methodological limitations and a high risk of bias in the underlying studies. The report highlights the contradictory effects of certain herbs, such as the *Hypericum* genus, where promising animal data conflicts with crucial human safety concerns. It also addresses the absence of a purported "breakthrough study," reframing the discussion around the need for rigorous, high-quality research to substantiate early findings. A dedicated section synthesizes safety data, emphasizing common gastrointestinal side effects and, more critically, the widespread potential for significant drug-herb interactions, particularly via the cytochrome P450 (CYP) enzyme system. This section provides an essential cautionary framework for clinical application. The field of botanical medicine for hyperlipoproteinemia remains in its infancy. While compelling leads exist, definitive clinical proof and robust safety data are largely absent. This report underscores the urgent need for a new generation of well-designed, transparent, and long-term randomized controlled trials to bridge the gap between preliminary findings and clinical validation.

1. Introduction: The Evolving Landscape of Hyperlipoproteinemia Management

Hyperlipoproteinemia, characterized by elevated levels of lipids such as cholesterol and

triglycerides in the bloodstream, is a pervasive and significant risk factor for cardiovascular diseases, including atherosclerosis, stroke, and heart attack.¹ Conventional pharmacological treatments, most notably statins, have proven highly effective in controlling lipid levels and reducing cardiovascular risk.¹ However, these therapies are often associated with side effects, leading to treatment intolerance or a reluctance among some patient populations to initiate therapy.³ This has spurred a growing and widespread interest in alternative and complementary approaches, particularly those derived from medicinal plants and natural ingredients.⁴

The use of natural compounds to lower blood lipids is a trend driven by both epidemiological observations and the search for solutions that may have fewer or different side effects than conventional drugs.⁵ The rationale for this shift is rooted in the idea that natural products may offer a lower-cost, lower-risk approach to managing hyperlipidemia, particularly when conventional therapies are either not tolerated or not able to fully control the disease.¹ However, the use of these substances by patients is often arbitrary, with unknown dosages and the potential for interference with conventional drugs and disease control.⁵ This highlights a crucial need for a rigorous, evidence-based analysis to move beyond anecdotal use and establish a scientific foundation for their clinical application. The goal is to identify functional, mechanism-based alternatives that could be used either alone or as adjuncts to existing care, especially for statin-intolerant patients.³

2. A "Breakthrough Study" Under Scrutiny: The Case of Varma, K. B. K., et al. (2024)

A specific request was made to locate and analyze a "breakthrough study" on hyperlipoproteinemia by Varma, K. B. K., et al. (2024). A comprehensive review of the available research material did not yield any publication matching this description. The provided documents referencing the author's initials, K.B.K. and Varma, are from unrelated fields or different timeframes. For instance, one publication involves a review of carbon nanotubes for microfluidic applications, with a co-author named K.B.K..⁷ Another source mentions a paper on postprandial hyperlipidemia from 2016, where an author named K.B.K. contributed but was not the primary author.⁸

The term "breakthrough study" itself appears in other provided sources, but in a non-academic context.¹ One document uses the phrase to introduce a general review of natural ingredients for hyperlipidemia, positioning the review itself as a "breakthrough study".¹ This non-specific, promotional use of the term contrasts sharply with the rigorous standards of scientific inquiry. It underscores a crucial disconnect between public perception and

scientific reality; what is often marketed as a "breakthrough" may simply be a broad review or preliminary research, not a definitive, paradigm-shifting clinical trial. For a medical expert, this warrants a cautious and skeptical approach to such claims and emphasizes the importance of scrutinizing the underlying data for methodological rigor and reproducibility. The lack of a single, landmark study suggests that a true scientific breakthrough in this field, defined by high-quality, replicable, and independently validated human trials, remains a rare and anticipated event.

3. In-Depth Analysis of Targeted Compounds: Efficacy and Mechanisms of Action

3.1. Berberine: A Comprehensive Overview

Berberine, a compound with a long history in traditional Chinese medicine, has emerged as one of the most promising natural therapies for dyslipidemias. A systematic review and meta-analysis of 16 randomized clinical trials involving 2147 participants found that berberine significantly improved lipid profiles.¹⁰ Specifically, the analysis demonstrated a significant reduction in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG).¹⁰ The mean difference (MD) for TC was -

0.47 mmol/l (95% CI [-0.64, -0.31]), for LDL-C was -0.38 mmol/l (95% CI [-0.53, -0.22]), and for TG was -0.28 mmol/l (95% CI [-0.46, -0.10]), with all results being highly statistically significant ($p < 0.00001$ for TC and LDL-C, $p = 0.002$ for TG).¹⁰ When used as a standalone therapy, berberine also showed a significant increase in high-density lipoprotein cholesterol (HDL-C) with an MD of

0.08 mmol/l (95% CI [0.03, 0.12]).¹⁰

The mechanisms by which berberine exerts its lipid-lowering effects are distinct from those of statins, making it a potentially valuable adjunct or alternative therapy.³ Berberine is thought to upregulate the expression of low-density lipoprotein receptors (LDLR) on hepatocytes by stabilizing the messenger RNA (mRNA) transcripts that code for these receptors.³ This action enhances the liver's ability to clear LDL-C from the bloodstream.¹¹ Furthermore, berberine is believed to suppress the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) by accelerating the degradation of hepatocyte nuclear factor 1 α (HNF1 α) and

decreasing PCSK9 mRNA transcription.³ By influencing the PCSK9 pathway, berberine's effects are particularly relevant given the recent development of PCSK9 inhibitor drugs.³ Other mechanisms include the activation of AMP-activated protein kinase (AMPK), which suppresses lipid synthesis and promotes their breakdown, and the inhibition of bile salt hydrolase (BSH) in the gut, which affects cholesterol metabolism.¹¹

Despite the compelling quantitative findings from the meta-analyses, a critical review reveals several significant limitations.³ The included trials were noted for their high clinical heterogeneity, and the methodological quality of the majority of studies was generally low.¹⁰ Issues with random sequence generation, allocation concealment, blinding, and incomplete outcome data were prevalent, introducing a high risk of bias.³ Therefore, while the statistical results are promising, the authors of the meta-analysis advise that the findings should be interpreted with caution.¹⁰ A meta-analysis can increase statistical power, but if the underlying studies are flawed, the pooled results are also compromised. This underscores the urgent need for a large-scale, well-designed, randomized controlled trial to provide definitive clinical evidence for berberine's efficacy and safety.

3.2. *Basella alba*: From *In Vitro* Promise to Clinical Reality

Preliminary research has identified *Basella alba* (Malabar spinach) as a plant with significant potential for hypercholesterolemia treatment. In an *in vitro* screening of 25 medicinal plant methanol extracts for anti-HMG-CoA reductase activity, *Basella alba* leaf extract showed the highest inhibitory effect at approximately 74%.⁴ The enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the mevalonate pathway, which is responsible for cholesterol biosynthesis in the liver.¹³ The inhibition of this enzyme is the primary mechanism of action for statin drugs.⁴

Phytochemical analysis of the *Basella alba* leaf extract using gas chromatography with tandem mass spectrometry (GC-MS/MS) and reversed-phase high-performance liquid chromatography (RP-HPLC) revealed the presence of several compounds known to have antihypercholesterolemic effects.⁴ These include naringin, apigenin, luteolin, and

α-tocopherol, among others.⁴ The identification of these compounds provides a plausible mechanistic basis for the observed HMG-CoA reductase inhibitory activity.⁴

However, the findings are currently limited to an *in vitro* setting. The researchers themselves have emphasized that the hypocholesterolemic effects of *Basella alba* have "not been investigated to date" in living organisms.⁴ The study concludes by stating that further

investigation of

in vivo models should be performed to confirm its potential as an alternative treatment for hypercholesterolemia.¹³ This highlights a crucial gap in the research: the scientific process dictates that a compound must progress from laboratory research to animal models and then to humans to validate its efficacy and safety. The promising

in vitro data on HMG-CoA reductase inhibition serves as a strong signal for drug discovery but is not a substitute for clinical proof.

3.3. The *Hypericum* Genus: A Case of Contradictory Evidence

The research on the *Hypericum* genus presents a complex and contradictory picture. While the query specifically mentioned *Hypericum lysimachoides*, the provided literature primarily focuses on *Hypericum perforatum*, commonly known as St. John's Wort. The data from animal models appears encouraging, with an ethanol extract of *Hypericum lysimachoides* significantly lowering total cholesterol and LDL-C levels in hypercholesterolemic rabbits.¹⁵ Similarly, an extract of

Hypericum perforatum was shown to significantly decrease LDL-C in hyperlipidemic rats and restrict atherosclerotic lesions.¹⁶ These findings suggest a potential hypolipidemic effect of the herb when used alone.

However, a critical analysis of the clinical data on *Hypericum perforatum* reveals a completely different and far more significant clinical picture. When used in human patients, St. John's Wort has been shown to cause an increase in total cholesterol and LDL cholesterol levels, particularly in those taking statins.¹⁷ For instance, in patients on simvastatin, St. John's Wort increased LDL-C from

2.30 mmol/L to 2.72 mmol/L ($p < 0.0001$), and total cholesterol increased from 4.56 mmol/L to 5.08 mmol/L ($p < 0.0001$).¹⁷

The underlying mechanism for this paradoxical effect is a critical clinical consideration. St. John's Wort is a potent inducer of the cytochrome P450 3A4 (CYP3A4) enzyme system.¹⁷ This enzyme is responsible for the metabolism of a vast number of drugs, including many statins such as simvastatin, lovastatin, and atorvastatin.¹⁸ The induction of CYP3A4 by St. John's Wort accelerates the metabolism of the statin drug, leading to significantly decreased blood concentrations and a subsequent reduction in its therapeutic efficacy.¹⁷ This real-world, clinical-level interaction far outweighs the preliminary findings from animal studies and serves as a powerful cautionary tale about the complexities of botanical pharmacology. It strongly

suggests that St. John's Wort should be avoided in patients with hypercholesterolemia, especially those on statin therapy.¹⁷

3.4. *Alpinia pricei* and *Cuminum cyminum* L.: Preliminary Findings

Research on *Alpinia pricei* has so far been confined to animal models. A study in Syrian hamsters demonstrated that ethanol extracts of *A. pricei* rhizome had both "suppressive and preventive potencies against hypercholesterolemia".²¹ Hamsters fed a hypercholesterolemic diet and treated with a high dose of the extract showed lower serum levels of total cholesterol and LDL-C, suggesting a beneficial effect on lipid profiles.²²

Cuminum cyminum L. (cumin) is primarily known for its anti-diabetic and anti-inflammatory properties, but its essential oils have also demonstrated hypolipidemic effects.²³ Research using molecular docking and

in vivo models suggests that cumin essential oil nanocapsules may have hypocholesterolemic effects by interacting with HMG-CoA and down-regulating inflammatory markers.²³ However, the lipid-lowering effects of cumin are generally discussed as secondary to its primary anti-diabetic action, and more specific research is needed to isolate and confirm these effects.²⁴

4. A Broader Perspective: Other Emerging and Promising Natural Compounds

4.1. Alfalfa (*Medicago sativa*): The Role of Saponins

Alfalfa has been investigated for its hypocholesterolemic and antiatherosclerotic properties, which are largely attributed to the presence of saponin glycosides.²⁵ Animal studies have shown that alfalfa can significantly reduce total cholesterol and LDL-C levels, with one study reporting decreases of 85.1% and 88%, respectively, in hypercholesterolemic rabbits.²⁵ The mechanism of action is believed to involve the neutralization of cholesterol in the stomach by

saponins, which then facilitates its excretion from the body.²⁵

The safety and standardization of alfalfa extracts are critical. The provided data highlights a need for proper extraction methods to produce an extract with a high saponin content while ensuring low levels of toxic constituents such as canavanine and coumestrol.²⁵ A limited human clinical trial involving 19 healthy male volunteers showed a trend towards decreased LDL and triglycerides and increased HDL, but these changes were not statistically significant.²⁶ The reliance on a specific growth stage of the plant to avoid toxic compounds underscores that the safety of a botanical compound is not guaranteed by its "natural" origin; it is a complex issue of sourcing, processing, and standardization.²⁵

4.2. Artichoke Leaf Extract: Recent Meta-Analytic Evidence

Artichoke leaf extract is another natural compound with promising evidence for lipid-lowering effects. A meta-analysis of 9 randomized controlled trials with 702 subjects found that artichoke extract supplementation was associated with a significant reduction in plasma concentrations of total cholesterol, LDL-C, and triglycerides.²⁷ The weighted mean difference (WMD) was -

17.6 mg/dL for total cholesterol and -14.9 mg/dL for LDL-C.²⁷ No significant effect on HDL-C was observed.²⁷

A particularly valuable finding from the analysis was that the LDL-lowering effect of artichoke was significantly associated with a patient's baseline LDL-C concentration.²⁷ This suggests that artichoke extract may be most effective in those who already have elevated lipid levels, potentially positioning it as a targeted therapy rather than a general supplement.²⁷ This moves the discussion beyond a simple question of efficacy to a more nuanced consideration of which patient population would benefit most from this intervention. The evidence suggests that artichoke extract could be a synergistic complement to lipid-lowering therapy, especially for patients with hyperlipidemia.²⁷

4.3. Fenugreek: Inconsistent but Encouraging Data

The clinical evidence for fenugreek's anti-hyperlipidemic properties is currently limited and inconsistent.²⁹ While a meta-analysis from 2020 found that fenugreek supplements may help lower cholesterol levels in people with diabetes, other studies on different populations have

yielded mixed results.²⁹ This variability may be attributed to the diverse populations studied, including general patients, diabetic patients, and postmenopausal women.²⁹

The research landscape for fenugreek is maturing, with new studies designed to address these limitations. For example, a new randomized clinical trial is specifically investigating the lipid-lowering effect of fenugreek seed tea in patients with hyperlipidemia *without* diabetes, a patient population that has not been specifically studied before.³⁰ The existence of this targeted trial demonstrates a crucial step in the scientific process: identifying the gaps in early, heterogeneous research and designing more rigorous studies to provide clearer, more definitive answers.²⁹

4.4. Other Noteworthy Herbs and Nutrients

Several other natural compounds show promising, albeit preliminary, results. Turmeric, for instance, contains the active component curcumin, which may protect patients at risk of cardiovascular disease by improving serum lipid levels.³¹ Ginger, a popular culinary herb, has also been linked to a reduction in triglyceride and LDL-C levels in low doses, though more high-quality studies are necessary to confirm its effectiveness.³¹ Other compounds like yarrow, holy basil, hawthorn, and flaxseed have also been investigated for their potential lipid-lowering effects, but robust clinical evidence is generally lacking or mixed.³¹

It is also important to consider more established natural therapies. Red yeast rice, for example, is a traditional Chinese medicine that contains monacolin K, a compound chemically identical to the statin lovastatin.³² While it can effectively lower cholesterol, its use is associated with the same potential side effects and drug interactions as lovastatin, and its quality can be highly variable, with some products containing little to no active ingredient or being contaminated with the kidney-damaging toxin citrinin.³²

5. Safety, Side Effects, and Critical Drug Interactions

The perception that "natural" means "safe" is a dangerous oversimplification. While many natural compounds are well-tolerated, they are not without risk. A comprehensive analysis of the safety profiles and potential interactions of these compounds is paramount for clinical application.

5.1. General Side Effects and Safety

The most commonly reported side effects across many of these natural compounds are related to the gastrointestinal system. These include diarrhea, constipation, gas, abdominal pain, and upset stomach, which have been reported for berberine, artichoke, and fenugreek.³⁴ Some unique side effects have also been noted, such as a maple-syrup-like body or urine odor associated with fenugreek consumption.³⁷ Allergic reactions are a risk, particularly for individuals with known sensitivities to specific plant families, such as the Asteraceae family (which includes artichoke, ragweed, and chamomile).³⁸ Furthermore, a significant concern exists with product quality. Studies have found that supplements, such as berberine, may not contain the labeled amount of the active ingredient.³⁵ The risk of contamination, as seen with citrinin in red yeast rice, further highlights the safety issues that can arise from a lack of regulatory oversight and standardization.³²

5.2. Critical Drug-Herb Interactions

The single most important clinical consideration for natural lipid-lowering compounds is their potential to interact with the cytochrome P450 (CYP) enzyme system in the liver and small intestine.³ This system is responsible for metabolizing a vast array of pharmaceuticals, and interactions can either decrease a drug's efficacy or increase its toxicity.

- **Berberine:** Berberine is an inhibitor of several key CYP enzymes, including CYP3A4, CYP2C9, and CYP2D6.³ By slowing the breakdown of medications metabolized by these enzymes, berberine can increase their blood levels, potentially leading to enhanced effects and an increased risk of side effects.³⁴ This interaction is of particular concern with drugs like tacrolimus, a potent immunosuppressant, where a severe interaction has been reported.³⁵
- **St. John's Wort:** As discussed previously, St. John's Wort is a potent CYP3A4 inducer, the opposite effect of berberine.¹⁷ This induction accelerates the metabolism of drugs, including statins like simvastatin, lovastatin, and atorvastatin, leading to a marked decrease in their blood concentration and a subsequent loss of therapeutic effect.¹⁷ This interaction is so significant that it is recommended to avoid St. John's Wort entirely in patients on statin therapy.¹⁷
- **Other Interactions:** Artichoke leaf extract has been shown to interact with certain medications broken down by the liver.³⁸ Berberine and fenugreek both possess blood-sugar-lowering and blood-pressure-lowering effects, which can have additive

effects when taken with antidiabetic or antihypertensive medications.³⁴ Close monitoring of blood glucose and blood pressure is therefore required to prevent hypoglycemia or hypotension.³⁴ Furthermore, berberine and fenugreek may increase the risk of bleeding when combined with anticoagulant or antiplatelet drugs like warfarin.³⁴

Other critical contraindications include the use of berberine during pregnancy and lactation due to the risk of uterine contractions and bilirubin toxicity in infants.³⁴ Artichoke and other related plants should be avoided by individuals with a biliary obstruction or a history of gallstones.³⁸

The pervasive potential for these botanical compounds to interact with the CYP450 enzyme system is the single most important clinical consideration. Because many conventional medications are metabolized by these same pathways, the concurrent use of seemingly harmless herbs can have serious, unpredictable, and potentially life-threatening consequences, rendering them ineffective or toxic. This necessitates a fundamental shift in perspective for both patients and clinicians, away from the simple "natural equals safe" heuristic and toward a thorough understanding of botanical pharmacology.

Compound	Common Side Effects	Critical Drug Interactions	Specific Warnings/Contraindications
Berberine	Diarrhea, constipation, gas, upset stomach ³⁴	Inhibits CYP2D6, 2C9, 3A4 (increases levels of many drugs); Additive effects with blood-sugar-lowering and blood-pressure-lowering drugs; Increased bleeding risk with anticoagulants ³	Avoid during pregnancy and lactation due to risk of uterine contractions and bilirubin toxicity ³⁴
<i>Hypericum</i>	Dizziness, headache, GI upset ¹⁷	Potent CYP3A4 inducer (decreases levels of many drugs, including statins, oral anticoagulants, HIV	Avoid in patients with hypercholesterolemia, especially those on statin therapy ¹⁷

		drugs) ¹⁷	
Artichoke	Abdominal pain, diarrhea, gas, nausea ³⁸	Interacts with liver-metabolized drugs; Additive effects with blood pressure and diabetes medications ³⁸	Do not use if pregnant, breastfeeding, or if you have biliary obstruction or allergies to the Asteraceae family ³⁸
Fenugreek	Gastrointestinal upset, change in body/urine odor, allergic reactions, low blood sugar ³⁶	Additive effects with blood-sugar-lowering and blood-pressure-lowering drugs; Increased bleeding risk with anticoagulants ³⁷	Monitor for hypokalemia when used with other potassium-lowering agents; cross-reactivity with other plants in the Fabaceae family (e.g., chickpeas, peanuts) ³⁷
Red Yeast Rice	Stomach pain, heartburn, gas, headache ³³	Same as lovastatin; Additive effects with statins, high-dose niacin, and fibrates; Interacts with cyclosporine and grapefruit juice ³³	Avoid if pregnant, breastfeeding, or with liver/kidney issues. Risk of citrinin contamination ³³

6. Conclusion and Future Outlook

The current body of evidence on novel and emerging botanical medicines for hyperlipoproteinemia presents a landscape of both significant promise and profound uncertainty. Compounds like berberine and artichoke leaf extract show compelling and statistically significant effects on lipid profiles, as demonstrated by meta-analyses of clinical trials. Their unique mechanisms of action, distinct from statins, make them attractive

alternatives or adjuncts to conventional therapy, particularly for statin-intolerant patients. However, this preliminary evidence is tempered by a critical review of the underlying research, which reveals pervasive methodological flaws, a high risk of bias, and significant clinical heterogeneity. This means that while the statistical findings are encouraging, they are not yet clinically definitive.

The field is still in its nascent stages, with many compounds—such as *Basella alba* and *Alpinia pricei*—only having been investigated in preliminary *in vitro* or animal studies. The starkly contradictory findings on the *Hypericum* genus, where promising animal data is completely overshadowed by a critical, real-world drug interaction, serve as a powerful cautionary tale about the complexities of botanical pharmacology. The most crucial finding from this analysis is the widespread potential for these natural compounds to cause significant and dangerous drug-herb interactions, particularly through the CYP450 enzyme system, which demands a fundamental shift in how they are perceived and used in a clinical setting.

The path forward is clear. To bridge the gap between preliminary findings and clinical validation, a new generation of high-quality, transparent, and long-term randomized controlled trials is urgently needed. These studies must address the limitations of past research by employing rigorous methodologies, sufficient sample sizes, and a focus on clinically meaningful outcomes beyond simple biomarker changes. Until such definitive evidence exists, natural compounds for hyperlipoproteinemia should be considered promising adjuncts or alternatives for specific patient populations, but only under strict professional medical supervision, with a meticulous assessment of their safety profiles and potential for significant drug interactions. This report serves as a foundational resource for navigating this complex and evolving field of medicine.

Works cited

1. WORLD JOURNAL OF PHARMACEUTICAL RESEARCH - AWS, accessed September 13, 2025, https://wjpr.s3.ap-south-1.amazonaws.com/article_issue/335a946412e604c7650822e289bff4cf.pdf
2. (PDF) Hyperlipidemia: A Review of the Novel Methods for the Management of Lipids - ResearchGate, accessed September 13, 2025, https://www.researchgate.net/publication/353293117_Hyperlipidemia_A_Review_of_the_Novel_Methods_for_the_Management_of_Lipids
3. Efficacy of Berberine Alone and in Combination for the Treatment of ..., accessed September 13, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5871262/>
4. hMg-coa reductase inhibitory activity and phytocomponent investigation of *Basella alba* leaf extract as a treatment for hypercholesterolemia - Dove Medical Press, accessed September 13, 2025, <https://www.dovepress.com/article/download/19972>
5. Medicinal plants and their bioactive compounds in the control of hyperlipidemia: A comprehensive review - ResearchGate, accessed September 13, 2025,

- https://www.researchgate.net/publication/378875592_Medicinal_plants_and_their_bioactive_compounds_in_the_control_of_hyperlipidemia_A_comprehensive_review
6. HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia - PMC, accessed September 13, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4298350/>
 7. Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges - PMC, accessed September 13, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8875995/>
 8. Precision Nutrition and Metabolic Syndrome Management - MDPI, accessed September 13, 2025, https://mdpi-res.com/bookfiles/book/681/Precision_Nutrition_and_Metabolic_Syndrome_Management.pdf?v=1738548060
 9. Joint Action - Acast, accessed September 13, 2025, <https://feeds.acast.com/public/shows/5e8c1453f335f8fc5483e9ce>
 10. Efficacy and safety of berberine for dyslipidaemias: A systematic ..., accessed September 13, 2025, https://www.researchgate.net/publication/327949734_Efficacy_and_safety_of_berberine_for_dyslipidaemias_A_systematic_review_and_meta-analysis_of_randomized_clinical_trials
 11. How does berberine reduce blood lipids and cholesterol? - Examine.com, accessed September 13, 2025, <https://examine.com/faq/how-does-berberine-reduce-blood-lipids-and-cholesterol/>
 12. pmc.ncbi.nlm.nih.gov, accessed September 13, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10684937/#:~:text=BBR%20lowers%20cholesterol%20by%20inhibiting,et%20al.%2C%202017\).](https://pmc.ncbi.nlm.nih.gov/articles/PMC10684937/#:~:text=BBR%20lowers%20cholesterol%20by%20inhibiting,et%20al.%2C%202017).)
 13. HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia - Semantic Scholar, accessed September 13, 2025, <https://www.semanticscholar.org/paper/HMG-CoA-reductase-inhibitory-activity-and-of-alba-a-Baskaran-Salvamani/79cfc16d7c104a4aab0395376e32c217199139c>
 14. HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia - PubMed, accessed September 13, 2025, <https://pubmed.ncbi.nlm.nih.gov/25609924/>
 15. The effect of ethanol extract of Hypericum lysimachioides on lipid, accessed September 13, 2025, https://www.researchgate.net/publication/6886743_The_effect_of_ethanol_extract_of_Hypericum_lysimachioides_on_lipid_profile_in_hypercholesterolemic_rabbits_and_its_in_vitro_antioxidant_activity
 16. Effect of hydroalcoholic extract of Hypericum perforatum on selected traditional and novel biochemical factors of cardiovascular diseases and atherosclerotic lesions in hypercholesterolemic rabbits: A comparison between the extract and

- lovastatin - ResearchGate, accessed September 13, 2025, https://www.researchgate.net/publication/230742808_Effect_of_hydroalcoholic_extract_of_Hypericum_perforatum_on_selected_traditional_and_novel_biochemical_factors_of_cardiovascular_diseases_and_atherosclerotic_lesions_in_hypercholesterolemic_rabbits_A
17. Does St. John's Wort (*Hypericum perforatum*) increase cholesterol levels? - Dr.Oracle AI, accessed September 13, 2025, <https://www.droracle.ai/articles/282882/will-st-john>
 18. Different effects of St. John's Wort on the pharmacokinetics of simvastatin and pravastatin., accessed September 13, 2025, https://www.researchgate.net/publication/298285792_Different_effects_of_St_John's_Wort_on_the_pharmacokinetics_of_simvastatin_and_pravastatin
 19. Statin drugs (drug interactions) | Research Starters - EBSCO, accessed September 13, 2025, <https://www.ebsco.com/research-starters/health-and-medicine/statin-drugs-drug-interactions>
 20. Can simvastatin and St. John's Wort (*Hypericum perforatum*) be taken together?, accessed September 13, 2025, <https://www.droracle.ai/articles/29150/can-simvastatin-and-st-johns-wort-be-taken-together>
 21. Selected spices and their combination modulate ... - OUCI, accessed September 13, 2025, <https://ouci.dntb.gov.ua/en/works/73r0Ax69/>
 22. *Alpinia pricei* Hayata rhizome extracts have suppressive and preventive potencies against hypercholesterolemia - PubMed, accessed September 13, 2025, <https://pubmed.ncbi.nlm.nih.gov/20561946/>
 23. In Silico and In Vivo Studies Reveal the Potential Preventive Impact of *Cuminum cyminum* and *Foeniculum vulgare* Essential Oil Nanocapsules Against Depression-like States in Mice Fed a High-Fat Diet and Exposed to Chronic Unpredictable Mild Stress - MDPI, accessed September 13, 2025, <https://www.mdpi.com/2218-0532/93/3/37>
 24. Insulinotropic and β -cell protective action of cuminaldehyde, cuminol and an inhibitor isolated from *Cuminum cyminum* in streptozotocin-induced diabetic rats | British Journal of Nutrition, accessed September 13, 2025, <https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/insulinotropic-and-cell-protective-action-of-cuminaldehyde-cuminol-and-an-inhibitor-isolated-from-cuminum-cyminum-in-streptozotocin-induced-diabetic-rats/557CFBF0890CFE2C25DC051914635170>
 25. Study of Hypocholesterolemic and Antiatherosclerotic Properties of *Medicago sativa* L. Cultivated in Egypt - ResearchGate, accessed September 13, 2025, https://www.researchgate.net/publication/232274645_Study_of_Hypocholesterolemic_and_Antiatherosclerotic_Properties_of_Medicago_sativa_L_Cultivated_in_Egypt
 26. Evaluation of the effect of *Medicago sativa* on Lipid Profile and Iron Indices in Healthy Volunteers | Iranian Journal of Pharmaceutical Sciences, accessed September 13, 2025, <https://journals.sbm.ac.ir/index.php/ijps/article/view/42670>

27. Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis, accessed September 13, 2025, https://www.researchgate.net/publication/317570591_Lipid-lowering_activity_of_artichoke_extracts_A_systematic_review_and_meta-analysis
28. The effect of artichoke on blood lipids - Study Summary - Examine.com, accessed September 13, 2025, <https://examine.com/research-feed/study/d30a6d/>
29. Fenugreek: A therapeutic complement for patients with borderline hyperlipidemia: A randomised, double-blind, placebo-controlled, clinical trial | Request PDF - ResearchGate, accessed September 13, 2025, https://www.researchgate.net/publication/312664275_Fenugreek_A_therapeutic_complement_for_patients_with_borderline_hyperlipidemia_A_randomised_double-blind_placebo-controlled_clinical_trial
30. Determining the Lipid Lowering Effect of Fenugreek Seed Tea | ClinicalTrials.gov, accessed September 13, 2025, <https://clinicaltrials.gov/study/NCT05858671>
31. The best herbs to help lower cholesterol - Medical News Today, accessed September 13, 2025, <https://www.medicalnewstoday.com/articles/herbs-to-help-lower-cholesterol-quickly>
32. 7 Natural Remedies for High Cholesterol - Healthline, accessed September 13, 2025, <https://www.healthline.com/health/heart-disease/natural-remedies-cholesterol>
33. Red yeast rice - Mayo Clinic, accessed September 13, 2025, <https://www.mayoclinic.org/drugs-supplements-red-yeast-rice/art-20363074>
34. BERBERINE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews, accessed September 13, 2025, <https://www.webmd.com/vitamins/ai/ingredientmono-1126/berberine>
35. Berberine benefits, dosage, and side effects - Examine.com, accessed September 13, 2025, <https://examine.com/supplements/berberine/>
36. Fenugreek: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 13, 2025, <https://www.rxlist.com/fenugreek/generic-drug.htm>
37. Fenugreek benefits, dosage, and side effects - Examine.com, accessed September 13, 2025, <https://examine.com/supplements/fenugreek/>
38. Globe Artichoke - Pharmasave, accessed September 13, 2025, <https://pharmasave.com/health/natural-products/globe-artichoke/>
39. Artichoke Uses, Benefits & Side Effects - Drugs.com, accessed September 13, 2025, <https://www.drugs.com/npc/artichoke.html>
40. Medication Interactions: Food, Supplements and Other Drugs | American Heart Association, accessed September 13, 2025, <https://www.heart.org/en/health-topics/consumer-healthcare/medication-information/medication-interactions-food-supplements-and-other-drugs>